Zhang Jialiang, M.D, Associate Researcher, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China and Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. My research is deeply rooted in the field of cancer epigenetics, with a particular focus on unraveling the intricate molecular mechanisms underlying the progression of gastrointestinal malignancies through the lens of RNA modifications. I am driven by the potential to identify novel therapeutic targets and improve clinical outcomes for patients suffering from these aggressive diseases. This unique interdisciplinary approach, blending molecular biology, bioinformatics, and clinical oncology, sets me apart in my field and positions me at the forefront of cutting-edge research. Served as a key investigator in multiple national research projects, including the National Natural Science Foundation of China (Youth Program) and the Postdoctoral Innovative Talent Support Program. Reported on the epigenetic mechanisms underlying the progression of gastrointestinal tumors, highlighting the critical roles of RNA modifications in tumor evolution. Published landmark papers in top-tier journals such as Nat Genet, Gut, Cancer Res, Cell Death & Differ, and Nat Commun, emphasizing the therapeutic potential of targeting RNA modifications in cancer treatment. These publications have not only contributed to the scientific community but have also garnered significant attention, with over 1,200 citations and a Google Scholar H-index of 13. Additionally, I am an active member of professional associations, including the Chinese Anti-Cancer Association, where I contribute to shaping the future of oncology research. I have a strong track record in writing and reviewing high-quality scientific manuscripts, with experience in guiding junior researchers. My expertise is primarily in the field of cancer epigenetics, an emerging area that combines basic and clinical research on RNA modifications, tumor evolution, and targeted therapies. I am actively involved in interdisciplinary research, integrating molecular biology, bioinformatics, and clinical oncology. I possess excellent skills in communication, leadership, and problem-solving, and I am committed to advancing the understanding and clinical translation of RNA modification research in cancer.